Lv21
160 积分 2025-04-15 加入
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
28天前
已完结
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
2个月前
已关闭
Lymphatic Transport of Proteins After Subcutaneous Administration
2个月前
已完结
Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
4个月前
已完结
Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?
4个月前
已完结
Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta‐analysis of randomized clinical trials
4个月前
已完结
Safety, tolerability, pharmacodynamics, and pharmacokinetics of CJC-1134-PC in healthy Chinese subjects and type-2 diabetic subjects
4个月前
已完结
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
4个月前
已完结
皖公网安备34019202002308
